pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
236
stories
12d
STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
stat
12d
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
12d
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
13d
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
13d
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
13d
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
13d
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
13d
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
13d
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
13d
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
14d
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
14d
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
14d
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
14d
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
14d
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
14d
China poses increasing security risk as US biotech innovation edge erodes
biospace
18d
Opinion: STAT+: A bill is supposed to protect U.S. biotech from Chinese competition. But there’s a loophole
stat
19d
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
endpoints
19d
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
biospace
20d
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
endpoints
21d
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
biopharma dive
21d
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
22d
Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'
fiercebiotech
24d
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
25d
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
25d
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
25d
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
26d
STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
stat
26d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
26d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
← prev
page 2 of 8
next →
